Xcout IntelPMV Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to PMV Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what PMV Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see PMV Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals is a company developing first-in-class p53 regulators for the treatment of cancer by harnessing the power of the p53 protein.
PMV Pharmaceuticals, Inc. at a glance
PMV Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Princeton, United States, founded in 2013. It is publicly listed (PMVP) with a market capitalisation of $71.5M. Xcout tracks 29 named people at PMV Pharmaceuticals, Inc., including Robert Ticktin (General Counsel, Chief Operating Officer & Company Secretary).
PMV Pharmaceuticals, Inc. leadership
- Robert TicktinGeneral Counsel, Chief Operating Officer & Company Secretary
- Michael CarulliChief Financial Officer
- Deepika JalotaChief Development Officer
- Deepika Jalota, Pharm.D.Chief Development Officer
- Philip HermanChief Commercial Officer
- David H. MackCo-Founder, Chief Executive Officer, President & Director
23 more named people on record for PMV Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
PMV Pharmaceuticals, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $70M | 7 named | |
| Series A | $30M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 PMV Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to PMV Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Similar pharmaceuticals company
Incyclix Bio is an oncology therapeutics company headquartered in Research Triangle Park, North Carolina. Founded by pioneers in CDK inhibitor discovery, research, and development, the company focuses on creating innovative cancer treatments.
Similar pharmaceuticals company
Cao Pharmaceuticals Inc. develops anti-cancer drugs utilizing natural anti-cancer compounds. The company focuses on research, product pipelines, and developing lead drug candidates for cancer treatment.
Similar pharmaceuticals company
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Similar pharmaceuticals company
Kartos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California. The company is dedicated to developing new therapies, including an investigational MDM2 inhibitor called navtemadlin.
Similar pharmaceuticals company
Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.
Similar pharmaceuticals company
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Biotech, Pharma
Mendus is a pharmaceutical company based in Sweden and the Netherlands that is dedicated to changing the course of cancer treatment by addressing tumor recurrence.
Similar pharmaceuticals company
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Biotechnology & Pharmaceuticals
SciTech Development L.L.C. is a clinical-stage specialty oncology pharmaceutical company that develops safer drug delivery platforms and targeted cancer therapeutics. The company's lead candidate, ST-001 nanoFenretinide, is a patented treatment designed for lymphoma and other cancer indications.
Similar pharmaceuticals company
Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.
Similar pharmaceuticals company
Pentixapharm Holding AG is a clinical-stage radiopharmaceutical company that develops first-in-class radiopharmaceutical diagnostics and therapeutics, focusing on CXCR4-targeted compounds. The company serves patients and healthcare providers by advancing drug candidates through clinical trials, including Phase III-ready programs.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of PMV Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for PMV Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →